AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
Phase 3
Completed
- Conditions
- Dyslipidaemia
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00654602
IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin
Phase 3
Completed
- Conditions
- Fredrickson Type IIa & Type IIb Dyslipidaemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT00654446
STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin Across Dose Ranges
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5625
- Registration Number
- NCT00654537
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 940
- Registration Number
- NCT00654485
Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4875
- Registration Number
- NCT00654407
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
Phase 3
Completed
- Conditions
- HypercholesterolemiaCarotid Artery Stenosis
- Interventions
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00654394
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart DiseaseAtherosclerosis
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653445
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00653965
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2340
- Registration Number
- NCT00654225
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4444
- Registration Number
- NCT00654173
© Copyright 2025. All Rights Reserved by MedPath